← Oscar Health overview

Oscar Health vs Molina Healthcare: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Oscar Health Inc (OSCR)

Q3 2026
▲3▼1

Oscar Health raised guidance, launched AI marketplace, but risks remain

  • Record first half and raised 2026 guidance Oscar Health reported a record first half and raised its 2026 operating profit guidance by $250 million to $500–$700 million, with membership up 46% to 2.96 million despite a weaker ACA market.

    This is a major positive development that directly boosted investor confidence and the stock price.

  • Investor day: doubled EPS, 2027 target, AI launch At its investor day, Oscar lifted 2026 guidance again, doubled EPS expectations, set a $4 EPS target for 2027, and launched Lucy, an AI marketplace connecting ~70 carriers.

    These forward-looking initiatives and targets signal strong future growth and innovation.

  • Analyst upgrades on surging estimates Analysts upgraded the stock on surging estimates, reflecting increased optimism about Oscar's financial trajectory.

    Analyst upgrades often drive positive price momentum and validate the company's outlook.

  • Persistent risks: costs, CMS checks, valuation However, risks persist: guidance still implies a large second-half operating loss, outpatient and industry medical costs remain elevated, CMS eligibility checks could cause enrollment losses, and some fair-value estimates sit below the current price.

    These factors could pressure the stock and temper the positive outlook.

August 2026
▲3▼1

Oscar raises guidance, targets $4 EPS, launches Lucy marketplace

  • Oscar raises 2026 guidance and targets $4 EPS by 2027 At its investor day, Oscar raised 2026 earnings guidance by $100 million, doubled this year's EPS expectation, and set a $4 EPS target for 2027. It credited favorable medical cost trends and a better medical loss ratio. Higher expected profits make the stock more attractive.

    This is the biggest new fundamental catalyst, directly raising future earnings expectations.

  • New Lucy AI marketplace opens a new growth channel Oscar launched Lucy, an AI-driven marketplace connecting about 70 carriers with consumers and brokers for ACA and supplemental plans. It also sees a chance to move employer coverage into the ACA. A new business line could add revenue and profit beyond its own insurance plans.

    This is a new business initiative that could expand Oscar's addressable market and long-term growth.

  • Analyst upgrade on surging earnings estimates Oscar was upgraded to Zacks Rank #1 Strong Buy after its consensus earnings estimate jumped 290% in three months. The upgrade reflects the improved profit outlook and could draw more institutional buyers, though it is a backward-looking signal based on estimate revisions.

    It shows the market's earnings expectations have risen sharply, which can support the stock price.

  • Industry medical costs stay high, pressuring managed care CVS Health said at a conference that medical costs remain elevated, and managed care stocks including Oscar fell. High medical costs can squeeze insurers' profits if they pay out more in claims. This is a real counterweight to Oscar's upbeat guidance.

    It is the main negative force this period and a risk to Oscar's cost outlook.

Latest
▲3▼1

Oscar raises guidance, targets $4 EPS, launches Lucy marketplace

  • Oscar raises 2026 guidance and targets $4 EPS by 2027 At its investor day, Oscar raised 2026 earnings guidance by $100 million, doubled this year's EPS expectation, and set a $4 EPS target for 2027. It credited favorable medical cost trends and a better medical loss ratio. Higher expected profits make the stock more attractive.

    This is the biggest new fundamental catalyst, directly raising future earnings expectations.

  • New Lucy AI marketplace opens a new growth channel Oscar launched Lucy, an AI-driven marketplace connecting about 70 carriers with consumers and brokers for ACA and supplemental plans. It also sees a chance to move employer coverage into the ACA. A new business line could add revenue and profit beyond its own insurance plans.

    This is a new business initiative that could expand Oscar's addressable market and long-term growth.

  • Analyst upgrade on surging earnings estimates Oscar was upgraded to Zacks Rank #1 Strong Buy after its consensus earnings estimate jumped 290% in three months. The upgrade reflects the improved profit outlook and could draw more institutional buyers, though it is a backward-looking signal based on estimate revisions.

    It shows the market's earnings expectations have risen sharply, which can support the stock price.

  • Industry medical costs stay high, pressuring managed care CVS Health said at a conference that medical costs remain elevated, and managed care stocks including Oscar fell. High medical costs can squeeze insurers' profits if they pay out more in claims. This is a real counterweight to Oscar's upbeat guidance.

    It is the main negative force this period and a risk to Oscar's cost outlook.

July 2026
▲2▼1

Oscar's record first half and raised guidance drive gains, but cost and policy risks linger

  • Record first-half profit and raised 2026 outlook Oscar reported record first-half earnings and lifted its full-year operating profit target by $250 million to $500–$700 million. That tells investors the core business is more profitable than expected, which supports a higher stock price.

    This is the main new event that changed the company's profit outlook and directly pushes the stock up.

  • Second-half loss implied and cost worries The raised full-year guidance still implies a second-half operating loss of roughly $393–$593 million. Analysts also flagged rising outpatient costs and possible enrollment losses from CMS eligibility checks, which could pressure future profits and the stock.

    This is the key counterweight that explains why the stock fell after the guidance hike and why future gains are not guaranteed.

  • Membership surges 46% despite weaker ACA market Oscar ended the second quarter with 2.96 million members, up 46% from a year earlier, even as overall ACA enrollment weakened after enhanced subsidies expired. That suggests Oscar is taking market share, which can drive future revenue and profit.

    This is a new update on membership growth, a core driver of Oscar's revenue and long-term value.

  • Analysts lift estimates but see limited upside After the strong first half, analysts raised earnings estimates and pointed to a low PEG ratio of 0.6. However, some fair-value estimates sit below the current price, and risks remain from subsidy shifts and rising medical costs, so the stock's path depends on sustained margin improvement.

    This shows how the market is repricing Oscar after the results, balancing optimism with valuation and policy risks.

▲2▼1

Oscar's record first half and raised guidance drive gains, but cost and policy risks linger

  • Record first-half profit and raised 2026 outlook Oscar reported record first-half earnings and lifted its full-year operating profit target by $250 million to $500–$700 million. That tells investors the core business is more profitable than expected, which supports a higher stock price.

    This is the main new event that changed the company's profit outlook and directly pushes the stock up.

  • Second-half loss implied and cost worries The raised full-year guidance still implies a second-half operating loss of roughly $393–$593 million. Analysts also flagged rising outpatient costs and possible enrollment losses from CMS eligibility checks, which could pressure future profits and the stock.

    This is the key counterweight that explains why the stock fell after the guidance hike and why future gains are not guaranteed.

  • Membership surges 46% despite weaker ACA market Oscar ended the second quarter with 2.96 million members, up 46% from a year earlier, even as overall ACA enrollment weakened after enhanced subsidies expired. That suggests Oscar is taking market share, which can drive future revenue and profit.

    This is a new update on membership growth, a core driver of Oscar's revenue and long-term value.

  • Analysts lift estimates but see limited upside After the strong first half, analysts raised earnings estimates and pointed to a low PEG ratio of 0.6. However, some fair-value estimates sit below the current price, and risks remain from subsidy shifts and rising medical costs, so the stock's path depends on sustained margin improvement.

    This shows how the market is repricing Oscar after the results, balancing optimism with valuation and policy risks.

Molina Healthcare Inc (MOH)

Q3 2026
▼3▲1

Molina beats Q2, raises guidance, but membership and ACA cuts weigh

  • Revenue decline and membership loss Molina's Q1 and Q2 revenues fell year over year, with Q2 down 4.8% to $10.9 billion and total membership dropping 14.3% to about 4.9 million. Fewer customers mean less premium income, which pressures future profits and the stock price.

    Shows the core demand problem that is dragging on MOH's price.

  • Q2 earnings beat and raised 2026 guidance Molina beat Q2 earnings estimates by 10.2% and raised its full-year 2026 adjusted EPS guidance to at least $5.25. This signals cost control is working and gives investors more confidence in future profits, which supports the stock.

    This is the main positive force behind MOH's price right now.

  • ACA business pullback starting 2027 Molina plans to sharply cut its Affordable Care Act plans from 2027, limiting them to six states and lowering premiums. This reduces future revenue and shows management sees ACA as unprofitable, which weighs on long-term growth expectations.

    A major strategic shift that changes Molina's future revenue mix and risk.

  • High medical care ratio and tariff risk Molina's medical care ratio rose to 92.2%, meaning it spent more of each premium dollar on patient care, and shares fell about 11% despite the earnings beat. New tariffs on generic drug imports could raise future costs, adding pressure.

    Explains why the stock dropped even after good earnings and highlights a new cost risk.

July 2026
▼3▲1

Molina beats Q2, raises guidance, but membership and ACA cuts weigh

  • Revenue decline and membership loss Molina's Q1 and Q2 revenues fell year over year, with Q2 down 4.8% to $10.9 billion and total membership dropping 14.3% to about 4.9 million. Fewer customers mean less premium income, which pressures future profits and the stock price.

    Shows the core demand problem that is dragging on MOH's price.

  • Q2 earnings beat and raised 2026 guidance Molina beat Q2 earnings estimates by 10.2% and raised its full-year 2026 adjusted EPS guidance to at least $5.25. This signals cost control is working and gives investors more confidence in future profits, which supports the stock.

    This is the main positive force behind MOH's price right now.

  • ACA business pullback starting 2027 Molina plans to sharply cut its Affordable Care Act plans from 2027, limiting them to six states and lowering premiums. This reduces future revenue and shows management sees ACA as unprofitable, which weighs on long-term growth expectations.

    A major strategic shift that changes Molina's future revenue mix and risk.

  • High medical care ratio and tariff risk Molina's medical care ratio rose to 92.2%, meaning it spent more of each premium dollar on patient care, and shares fell about 11% despite the earnings beat. New tariffs on generic drug imports could raise future costs, adding pressure.

    Explains why the stock dropped even after good earnings and highlights a new cost risk.

Latest
▼3▲1

Molina beats Q2, raises guidance, but membership and ACA cuts weigh

  • Revenue decline and membership loss Molina's Q1 and Q2 revenues fell year over year, with Q2 down 4.8% to $10.9 billion and total membership dropping 14.3% to about 4.9 million. Fewer customers mean less premium income, which pressures future profits and the stock price.

    Shows the core demand problem that is dragging on MOH's price.

  • Q2 earnings beat and raised 2026 guidance Molina beat Q2 earnings estimates by 10.2% and raised its full-year 2026 adjusted EPS guidance to at least $5.25. This signals cost control is working and gives investors more confidence in future profits, which supports the stock.

    This is the main positive force behind MOH's price right now.

  • ACA business pullback starting 2027 Molina plans to sharply cut its Affordable Care Act plans from 2027, limiting them to six states and lowering premiums. This reduces future revenue and shows management sees ACA as unprofitable, which weighs on long-term growth expectations.

    A major strategic shift that changes Molina's future revenue mix and risk.

  • High medical care ratio and tariff risk Molina's medical care ratio rose to 92.2%, meaning it spent more of each premium dollar on patient care, and shares fell about 11% despite the earnings beat. New tariffs on generic drug imports could raise future costs, adding pressure.

    Explains why the stock dropped even after good earnings and highlights a new cost risk.